D&A at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's D&A?
- Jazz Pharmaceuticals (JAZZ) reported D&A of $172.3M in Q1 2026.
- How has Jazz Pharmaceuticals's D&A changed year-over-year?
- Jazz Pharmaceuticals's D&A increased by 11.6% year-over-year, from $154.4M to $172.3M.
- What does D&A mean?
- Non-cash expense representing the aging of assets and intangible property.
- How do you interpret D&A?
- Higher levels often correlate with significant capital investment or recent acquisitions of intangible assets, whereas lower levels may indicate aging assets or limited investment.
- How does D&A compare across companies?
- Standard accounting metric; high in capital-intensive or acquisition-heavy industries like pharmaceuticals.